Abstract: The disclosed methods, assays and kits identify biomarkers, particularly miRNA and/or protein biomarkers, for assessing the cardiovascular health of a human. In certain embodiments, methods, assays and kits, circulating miRNA and/or protein biomarkers are identified for assessing the cardiovascular health of a human.

Abstract: Agents that inhibit or prevent restenosis are identified by assaying test agents in a battery of assays to measure the effect of the test agent on cell proliferation, thrombosis, tissue modeling, and inflammation. Treatment for restenosis is provided using compositions of the invention.

Abstract: Agents that inhibit or prevent restenosis are identified by assaying test agents in a battery of assays to measure the effect of the test agent on cell proliferation, thrombosis, tissue modeling, and inflammation. Treatment for restenosis is provided using compositions of the invention.

Abstract: The disclosed methods, assays and kits identify biomarkers, particularly miRNA and/or protein biomarkers, for assessing the cardiovascular health of a human. In certain embodiments, methods, assays and kits, circulating miRNA and/or protein biomarkers are identified for assessing the cardiovascular health of a human.

Abstract: Agents that inhibit or prevent restenosis are identified by assaying test agents in a battery of assays to measure the effect of the test agent on cell proliferation, thrombosis, tissue modeling, and inflammation. Treatment for restenosis is provided using compositions of the invention.

Abstract: The present invention identifies two circulating proteins that have been newly identified as being differentially expressed in atherosclerosis. Circulating levels of these two proteins, particularly as a panel of proteins, can discriminate patients with acute myocardial infarction from those with stable exertional angina and from those with no history of atherosclerotic cardiovascular disease. Such levels can also predict cardiovascular events, determine the effectiveness of therapy, stage disease, and the like. For example, these markers are useful as surrogate biomarkers of clinical events needed for development of vascular specific pharmaceutical agents.

Abstract: Methods are provided for evaluating biological dataset profiles, where datasets comprising information for multiple cellular parameters are compared and identified. A typical dataset comprises readouts from multiple cellular parameters resulting from exposure of cells to biological factors in the absence or presence of a candidate agent. For analysis of multiple context-defined systems, the output data from multiple systems may be concatenated.

Abstract: The present invention identifies circulating proteins that are differentially expressed in atherosclerosis. Circulating levels of these proteins, particularly as a panel of proteins, can discriminate patients with acute myocardial infarction from those with stable exertional angina and from those with no history of atherosclerotic cardiovascular disease. Such levels can also predict cardiovascular events, determine the effectiveness of therapy, stage disease, and the like. For example, these markers are useful as surrogate biomarkers of clinical events needed for development of vascular specific pharmaceutical agents.

Abstract: Displays of genetic and/or proteomic expression data can be visually correlated by a user analyzing such expression data. Generally, the user identifies expression data, such as a cluster, a gene, or a protein for example, using conventional user interface techniques. Once expression data are identified by the user, corresponding expression data is identified in other displays. Such corresponding expression data is determined by reference to expression metadata. For each of the other displays of expression data, the corresponding expression data of the other displays is determined according to the expression metadata of those other displays. Within each of those other displays, the corresponding expression data is highlighted within the display to identify the corresponding expression data to the user.

Abstract: Results of statistical clustering and/or correlation analysis of genetic or proteomic expression data such as microarrays, gene chips, or protein chips are used, e.g., as response variables, in further analysis of expression data. In particular, an array of expression data is clustered using a cluster tool to produce an array of expression clusters. Each of the expression clusters represents the same experiments represented by the original expression array. Accordingly, each cluster of the array is of the proper form to be used as a response variable of expression values. Using an expression cluster as a response variable for either supervising clustering or correlation analysis allows correlation between such an expression cluster and other expression data.